Cronos Group（7CI）株式概要カンナビノイド企業であるクロノス・グループ社は、カナダ、イスラエル、および国際的な大麻製品の栽培、生産、流通、販売に従事している。 詳細7CI ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長3/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より67.2%で取引されている 収益は年間35.21%増加すると予測されています リスク分析リスクチェックの結果、7CI 、リスクは検出されなかった。すべてのリスクチェックを見る7CI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€2.4084.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-310m929m2016201920222025202620282031Revenue US$203.5mEarnings US$30.0mAdvancedSet Fair ValueView all narrativesCronos Group Inc. 競合他社Dermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.4bPEPTONIC medicalSymbol: DB:28LMarket cap: €560.2mCantourage GroupSymbol: XTRA:HIGHMarket cap: €75.3mBayerSymbol: XTRA:BAYNMarket cap: €37.8b価格と性能株価の高値、安値、推移の概要Cronos Group過去の株価現在の株価CA$2.4052週高値CA$3.0652週安値CA$1.57ベータ1.231ヶ月の変化9.31%3ヶ月変化8.42%1年変化36.99%3年間の変化47.26%5年間の変化-65.99%IPOからの変化5.92%最新ニュースお知らせ • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.お知らせ • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.お知らせ • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.お知らせ • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.お知らせ • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.お知らせ • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.最新情報をもっと見るRecent updatesお知らせ • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.お知らせ • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.お知らせ • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.お知らせ • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.お知らせ • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.お知らせ • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.お知らせ • Oct 28Cronos Group Inc. Brings Back Popular, Limited-Edition Spinach Green Apple-Flavored Products for the Fall SeasonCronos Group Inc. announced that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet caramel and tart-green apple flavors and is perfect for the autumn months, follows its successful launch in Fall 2024. In addition to bringing back the original SOURZ by Spinach Caramel Green Apple 5-pack of gummies, Cronos is expanding its Fall season exclusive offerings with two new products: SOURZ by Spinach Fully Blasted Caramel Green Apple 10mg THC gummy; Spinach Sweet Green Apple 1g vape (Sativa): Infused with liquid diamonds and featuring crisp green apple flavor notes. These limited-time, seasonal Spinach products are available now across Canada.お知らせ • Oct 09Cronos Group Inc. Launches Sourz by Spinach Fully Blasted MultipacksCronos Group Inc. announced that its popular SOURZ by Spinach Fully Blasted gummies will now be available in new multipack formats. The SOURZ by Spinach fully Blasted Multipacks with liquid diamond-infused gummies are now available in five of its most popular flavors, offering consumers more choice, convenience, and value when purchasing Canada's favorite cannabis edible. SOURZ by Spinach Fully Blasted Multipacks with Liquid diamond-infused gummies will be available in 5- and 10-packs in the following flavors: 10-Pack (10 x 10mg THC gummies): SOURZ by Spinach Fully Blasted Blue Raspberry Watermelon gummies; SOURZ by Spinach Fully Blasted Pink Lemonade gummies; SOUR Z by Spinach FullyBlasted Strawberry Mango gummies: SOURZ by spinach Fully Blasted Peach Orange gummies; 5-Pack (5 x 10mg THC gummies); SOURZ by Spinach- Fully Blasted Blue Raspberry Water Watermelon gummies; SourZ by Spinach fully Blasted Pink Lemonade gibles; SOURZ by SpinACH Fully Blasted Strawberry Mango gummies; SOURZ By Spinach Fully Blasting Peach Orange gummies; 5 -Pack (5 x 10mgTH gummies); SOURZ By Spinach Fully Blasting Peach Orange Gummies; 5-Pack (5 x 10mg THC gummies; SOURZby Spinach Fully Blast Blue Raspberry Watermelon gummies and SOURZ by Spinach? Fully Blasted Pink Lemonades gummies. The SOURZ by spinach Fully Blasted Multipack with liquid diamond-infused Gummies are available now in Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan.お知らせ • Aug 07Cronos Group Inc. Appoints Lloyd Wilson as the Principal Accounting Officer, Effective as of August 7, 2025Cronos Group Inc. Appointed Lloyd Wilson, Vice President, Controller, as the Company’s principal accounting officer, effective as of August 7, 2025. Lloyd is a seasoned financial leader and licensed Chartered Public Accountant with over 20 years of experience in financial reporting, internal audit, plant controllership, and operational finance. With a strong background in consumer-packaged goods and previous experience as a plant controller, Lloyd most recently served as a Corporate Controller, where he oversaw financial reporting, internal controls, and policy implementation.お知らせ • May 09Cronos Group Inc. (TSX:CRON) announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.Cronos Group Inc. (TSX:CRON) announces a share repurchase program. Under the program, the company will repurchase up to 19,270,951 shares representing 5% of it's issued share for $50 million. The repurchases will be made from available funds. The repurchase program is valid till May 13, 2026.お知らせ • Apr 23Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare CannabinoidsCronos Group Inc.'s best-selling cannabis brand, Spinach®?, introduced three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach®? Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio. Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio; Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.; Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach®? vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience. In addition to the Spinach®? vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach™?, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors: Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy.お知らせ • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2025Cronos Group Inc., Annual General Meeting, Jun 20, 2025.お知らせ • Mar 20Cronos Group Inc. Announces Chief Financial Officer ChangesCronos Group Inc. announced the appointment of Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success. Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.004 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.02 (up from US$0.004 loss in 3Q 2023). Revenue: US$34.3m (up 38% from 3Q 2023). Net income: US$8.35m (up US$9.81m from 3Q 2023). Profit margin: 24% (up from net loss in 3Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Aug 28Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across CanadaCronos Group Inc. is expanding its portfolio for its Lord Jones brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. The Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes: Lord Jones Ice Water Hash Fusions Pre-Rolls: Sour Blueberry x Sour Blueberry. 1g ice water hash flower pre-roll with blueberry and gas flavor notes. Indica | THC: 35-41% | 1x1g. Snow Lotus x Animal Mints. 1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes. Hybrid | THC: 35-41% | 1x1g Lord Jones Live Resin Vapes (All-in-One and 510-Cartridge): Gorilla Z Live Resin Vape A flavor-forward vape designed to boast an promoted berry, cherry, and grape flavor experience. Hybrid | 70+% THC . Available in two hardware options that are optimized for live resin usage: A sleek 0.5g all-in-one device. A high-quality 1g 510-thread cartridge.Breakeven Date Change • Aug 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$24.7m in 2026.Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.02 loss per share (vs US$0.015 loss in 2Q 2023)Second quarter 2024 results: US$0.02 loss per share (further deteriorated from US$0.015 loss in 2Q 2023). Revenue: US$27.8m (up 46% from 2Q 2023). Net loss: US$8.76m (loss widened 59% from 2Q 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 5 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.Breakeven Date Change • Jul 13No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.47m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.Breakeven Date Change • Jul 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.69m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.お知らせ • Jun 28Cronos Group Inc. Brand Spinach®? Celebrates Summer with New LaunchesCronos Group Inc.'s Spinach®? brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach®? edibles and a premier milled flower product. The new SOURZ by Spinach™? Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ®? flavors, now with 10 mg of THC per piece. The SOURZ by SpinACH®? Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach®? "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. SOURZ by SpinachTM Fully Blasted includes one 10 mg THC gummy per package in the following flavors: Pink Lemonade; Sweet and refreshing flavors of raspberry and lemonade; Blue Raspberry Watermelon; Electric blue raspberry and refreshing watermelon; Cherry Lime; Delightful cherry and tangy lime. SOURZ by SpinACH™? Tropical Party Pack: 1 mg THC per gummy, 10 mg THC per pack; Featuring three new dual-flavors: Peach Passionfruit, Pineapple Coconut, and Strawberry Guava. Additionally, the Spinach®? brand will introduce Spinach®?, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™? caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience. Spinach Grindz®? are now available in the following strains: Citrus Crush; Milled flower with citrus, sour, and earthy notes; Cookie Dough; Milled flower with sweet, nutty, and creamy notes.お知らせ • Jun 22Cronos Group Inc. Elects Murray Garnick as DirectorCronos Group Inc. at its Annual Meeting of Shareholders held on June 20, 2024, approved to elect Murray Garnick as director.Breakeven Date Change • May 12Forecast breakeven date moved forward to 2025The 8 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 87% to 2024. The company is expected to make a profit of US$5.67m in 2025. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • May 10First quarter 2024 earnings released: US$0.01 loss per share (vs US$0.05 loss in 1Q 2023)First quarter 2024 results: US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023). Revenue: US$25.3m (up 26% from 1Q 2023). Net loss: US$2.24m (loss narrowed 88% from 1Q 2023). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 07No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.71m in 2026. New consensus forecast suggests the company will make a loss of US$1.60m in 2026.New Risk • Mar 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2024Cronos Group Inc., Annual General Meeting, Jun 20, 2024.お知らせ • Mar 26Cronos Group Inc. Launches Lord Jones Chocolate FusionsCronos Group Inc. announced the launch of Lord Jones Chocolate Fusions, its exciting first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi- texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Lord Jones Chocolate Fusions feature winning attributes to attract cannabis consumers, including three delicious flavor combinations, an artisanal design that highlights a creative combination of textures, and a flavor-masking system to ensure outstanding taste. Through an extensive research and sensory testing process, team of experts seized the opportunity to deliver an exceptional edible that elevates the overall category. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Chocolate Fusions will be available in the following flavors and formats: Lord Jones Cookies & Cream Chocolate Fusions, 10mg THC total per package, Three layers of white chocolate, cookie crunch bits, and a chewy fudge center, Lord Jones Salted Caramel Crunch 1:1 CBD | THC Chocolate Fusions, 10mg CBD per package, 10mg THC and 10mg CBD per package, Three layers of milk chocolate, a sweet and salty crunch, and a smooth caramel center, Lord Jones Dazzleberry Pop Chocolate Fusions, 10mgTH total per package, Three layers the gold-dusted dark chocolate, a crackling pop, and a sweet berry center. Cronos continues to be an award-winning leader in cannabis edibles. The same team behind the hugely popular SOURZ by Spinach® and Spinach FEELZTM portfolio of gummies leveraged their expertise in the edibles space to create this innovation for the chocolate category for the Lord Jones® brand.Breakeven Date Change • Mar 03Forecast breakeven date moved forward to 2025The 6 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 79% to 2024. The company is expected to make a profit of US$11.0m in 2025. Average annual earnings growth of 48% is required to achieve expected profit on schedule.Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$236.3k in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule.お知らせ • Dec 15Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware OptionsCronos Group Inc. announced the launch of its highly anticipated Lord Jones Live Resin Vapes in two different hardware options. Crafted with the discerning cannabis consumer in mind, these products embody a commitment to excellence, offering an unmatched combination of curated strains, pure live resin, and elegant high-quality hardware. The live resin format offers consumers a multi-dimensional, true-to-plant experience. This format is well suited for discerning consumers looking to level-up their cannabis experience. These vapes feature consistent high potency, with THC levels exceeding 70%, and advanced hardware designed to optimize live resin consumption, preserving terpenes and preventing clogging. The lineup also features versatile sizing options, including a 0.5g trial size in the convenience of an all-in-one device and a 1g stock-up size as a 510-thread cartridge, catering to both enthusiasts and those new to the category. Lord Jones Live Resin Vape are available in the following formats: Lord Jones Purple Lemon Haze Live Resin Vapes; Designed to deliver a supremely elevated experience, with notes of zesty citrus, pleasant earthiness, and sharp and spicy pepper flavors; Sativa | THC: 72-78% Available in two hardware options that have been optimized for live resin usage: A unique sleek 0.5g all-in-one device; A high-quality 1g 510-thread cartridge; Lord Jones Deadhead OG Live Resin Vapes; designed to deliver a truly complex flavor experience with savory, spicy, and woody flavors; Indica | THC: 71-77% Available in two hardware options That have been optimized for live resin use: A unique sleek 0. 5g all-in-one devices will be available in Alberta, Manitoba, Ontario, Saskatchewan and Yukon in 2024. Lord Jones batteries will be available in Manitoba, Ontario, Saskatchewan andYukon by early 2024. Lord Jones batteries will been available in Manitoba, Ontario, Alberta, Ontario, Saskatchewan and YukON by early 2024.お知らせ • Nov 29Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million on November 26, 2023. The aggregate purchase price will be paid as CAD 0.1 million will be paid in trust within two business days of the date of the Sale Agreement (b) CAD 1 million will be paid in trust within five business days of the waiver or satisfactions of the Buyer’s Condition, the Seller’s Condition and the Lease Condition (each, as defined below) and (c) the balance of the aggregate purchase price will be paid at the closing. Closing is expected to occur on the first business day that falls 30 calendar days following the later of (i) the satisfaction or waiver of the Buyer’s Condition or (ii) the satisfaction or waiver of the Seller’s Condition.Breakeven Date Change • Nov 11Forecast to breakeven in 2025The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of US$7.29m in 2025. Average annual earnings growth of 92% is required to achieve expected profit on schedule.Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022)Third quarter 2023 results: US$0.005 loss per share (improved from US$0.098 loss in 3Q 2022). Revenue: US$24.8m (up 19% from 3Q 2022). Net loss: US$1.46m (loss narrowed 96% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Nov 04Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis MarketCronos Group Inc. announced that it has launched its award-winning cannabis brand Lord Jones® in the Canadian adult-use cannabis market. The Lord Jones® brand will build on its legacy of delivering premium quality cannabis products by returning to its roots with bold THC-focused product innovations. The first Lord Jones® product to launch in Canada are Lord Jones® Hash Fusions pre-rolls. The popularity of hash products and premium pre-rolls is increasing amongst adult consumers. Hash is currently the most popular solventless infusion and is the second most popular infusion overall in the pre-roll category. The Lord Jones® Hash Fusions pre-rolls go beyond delivering an elevated, true-to-plant consumption experience. These pre-rolls are crafted with an optimized ratio of premium high-potency flower and complementary solventless ice water hash, which preserves the buds’ natural terpenes, fitted with a reusable ceramic tip to help cool the smoke. This new product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. Lord Jones® Hash Fusions pre-rolls are available in the following formats: Lord Jones® Hash Fusions – White Tahoe OG Flower x White Tahoe OG Ice Water Hash; Indica | THC: 35 – 40% | 1x1g; Lord Jones® Hash Fusions – Cosmic Kush Flower x Platinum GMO Ice Water Hash; Hybrid | THC: 35 – 40%+| 1x1g.お知らせ • Oct 31Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full TiltCronos Group Inc. announced the launch of two new THCV-infused products; Spinach FEELZ Full Tilt THCV vape and gummy. Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ brand, which will add an additional offering under its robust and growing pre-roll portfolio. The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience. The Spinach FEELZ full Tilt product range includes: Spinach FEELZ FullTilt Blue Razz Durban 7:1 THC|THCV vape; 700mg of THC and 100mg of THCV per 1g cartridge; Spinach FEELZ fullTilt Blue Raspberry Lemonade 1:2 THC|THCV gummies; 5 pieces/pack with 10mg of THC and 20mg THCV per pack. The THCV vape is now available in Alberta, British Columbia, and Ontario and the THCV edibles are available now in Ontario and British Columbia and will be available in Alberta by November 30. THC infused pre-rolls are planned for launch in 2024. Through Spinach FEELZ, Cronos is committed to bringing a full line of products featuring rare cannabinoids to consumers in a wide range of product formats. Each product is designed to deliver unique and enhanced experiences made possible through proprietary blends of rare cannabinoids alongside more well-known cannabinoids, like THC and CBD. Each product is formulated to help adult consumers, "Feelz. The Way You want." With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®?, PEACE NATURALS®? and Lord Jones®?.お知らせ • Aug 10Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023Cronos Group Inc. revised earnings guidance for the full year 2023. For the year, the company has decided to discontinue providing net revenue guidance and to withdraw previously announced net revenue target of $100 million to $110 million for full-year 2023. The discontinuance of providing net revenue guidance reflects turbulent market conditions beyond previous expectations in the markets in which Company operate, specifically, increasing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada. In addition, foreign exchange rates have had unfavorable impact on Company's net revenue.Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.054 loss in 2Q 2022)Second quarter 2023 results: US$0.013 loss per share (improved from US$0.054 loss in 2Q 2022). Revenue: US$19.0m (down 18% from 2Q 2022). Net loss: US$5.53m (loss narrowed 73% from 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Jul 07Cronos Reportedly Explores Possible Sale After Attracting Takeover InterestCronos Group Inc. (TSX:CRON), the Canadian cannabis producer backed by cigarette maker Altria Group Inc. (MO.N), is exploring options that include a potential sale after attracting acquisition interest, people familiar with the matter said. Toronto-based Cronos is working with a financial adviser to handle the expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc. (CURA.CD), the sources said. The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain. Cronos and Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment.お知らせ • May 20Cronos Group Inc. Announces Executive ChangesOn May 18, 2023, Cronos Group Inc. appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023. On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023. Prior to joining the Company, Mr. McGinness, age 45, was the Acting Chief Financial Officer and Vice President, Corporate Controller for MarketWise Inc. since April 2019. While at MarketWise, Mr. McGinness was responsible for the Accounting, Tax, External and Internal Financial Reporting, Investor Relations, and Financial Planning and Analysis functions and was instrumental in restructuring and developing a world-class finance organization while shepherding MarketWise through an Up-C SPAC transaction and several other strategic transactions. Prior to MarketWise, Mr. McGinness served as Corporate Controller at GSE Systems from August 2016 until November 2018 and previously held various management roles at Exelon, Washington Gas, T. Rowe Price and McCormick. Mr. McGinness is a CPA and earned a Bachelor of Science in Accounting from the State University of New York at Albany.お知らせ • May 10Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023Cronos Group Inc. Provided revenue guidance for the full year 2023. For the year, the company expected to be between $100 million to $110 million.Reported Earnings • May 09First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.087 loss in 1Q 2022)First quarter 2023 results: US$0.10 loss per share. Revenue: US$20.1m (down 20% from 1Q 2022). Net loss: US$19.2m (loss narrowed 41% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Mar 01Full year 2022 earnings released: US$0.45 loss per share (vs US$1.07 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$1.07 loss in FY 2021). Revenue: US$91.9m (up 24% from FY 2021). Net loss: US$168.7m (loss narrowed 57% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.Board Change • Jan 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kendrick Ashton was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kendrick Ashton was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.054 loss per share (vs US$0.48 loss in 2Q 2021)Second quarter 2022 results: US$0.054 loss per share (up from US$0.48 loss in 2Q 2021). Revenue: US$23.1m (up 48% from 2Q 2021). Net loss: US$20.2m (loss narrowed 89% from 2Q 2021). Over the next year, revenue is forecast to grow 34%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.15 (vs US$0.31 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$15.6m (up 58% from 2Q 2020). Net income: US$57.6m (up US$164.5m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Executive Departure • Jul 13Executive Officer Puneet Mathur has left the companyOn the 30th of June, Puneet Mathur's tenure as Executive Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Puneet's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.46 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • May 09First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.22 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$12.6m (up 50% from 1Q 2020). Net loss: US$161.3m (down 312% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.Recent Insider Transactions • Mar 17Executive Chairman recently sold €5.2m worth of stockOn the 15th of March, Michael Gorenstein sold around 604k shares on-market at roughly €8.67 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by €13m.Recent Insider Transactions • Mar 05Insider recently sold €51k worth of stockOn the 1st of March, Jeffrey Jacobson sold around 5k shares on-market at roughly €11.28 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €14m more than they bought in the last 12 months.Reported Earnings • Feb 28Full year 2020 earnings released: US$0.20 loss per share (vs US$3.76 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$46.7m (up 97% from FY 2019). Net loss: US$72.5m (down 106% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 7.9%. Over the next year, revenue is forecast to grow 86%, compared to a 2.1% growth forecast for the Pharmaceuticals industry in Germany.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to US$10.20, the stock is trading at a trailing P/E ratio of 45.6x, down from the previous P/E ratio of 57x. This compares to an average P/E of 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 76%.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to US$10.44, the stock is trading at a trailing P/E ratio of 42.5x, up from the previous P/E ratio of 34.7x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 79%.Is New 90 Day High Low • Feb 03New 90-day high: €9.50The company is up 75% from its price of €5.43 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €20.51 per share.Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$9.25, the stock is trading at a trailing P/E ratio of 38.7x, up from the previous P/E ratio of 33.6x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 24%.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$8.88, the stock is trading at a trailing P/E ratio of 37x, up from the previous P/E ratio of 31.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 35%.Is New 90 Day High Low • Jan 07New 90-day high: €7.52The company is up 54% from its price of €4.87 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$7.06, the stock is trading at a trailing P/E ratio of 26.1x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 22%.Is New 90 Day High Low • Dec 04New 90-day high: €7.22The company is up 62% from its price of €4.46 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.17 per share.Valuation Update With 7 Day Price Move • Nov 27Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.00, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 137%.Recent Insider Transactions • Nov 12Executive Chairman recently sold €7.8m worth of stockOn the 6th of November, Michael Gorenstein sold around 1m shares on-market at roughly €6.08 per share. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 22% share price gain to US$5.76, the stock is trading at a trailing P/E ratio of 3.7x, up from the previous P/E ratio of 3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 102%.Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 18% share price gain to US$5.43, the stock is trading at a trailing P/E ratio of 2.9x, up from the previous P/E ratio of 2.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 148%.Is New 90 Day High Low • Nov 05New 90-day high: €5.09The company is up 1.0% from its price of €5.04 on 06 August 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.25 per share.お知らせ • Oct 15Cronos Group Inc. Announces the Launch of Happy Dance, A New, Clean, Simple CBD Skincare Brand, Co-Founded with Actress and New York Times Best-Selling Author Kristen BellCronos Group Inc. announced the launch of Happy Dance, a new, clean, simple CBD skincare brand, co-founded with actress and New York Times best-selling author Kristen Bell. Happy Dance launches with a trio of high-quality, cruelty-free and vegan bath and body care products. The new Happy Dance collection features a body butter, a coconut melt and a bath bomb, all formulated with Kristen Bell’s favorite clean ingredients and high-quality CBD from full-spectrum hemp extract. These multi-purpose products are infused with delightful blends of plant-based oils and butters in enjoyable textures that are effortlessly easy-to-use. The ultimate head-to-toe body treats, Happy Dance products are perfectly suited for the CBD enthusiast or for someone experiencing CBD for the first time. The Happy Dance brand is the epitome of good, clean, fun. The full-spectrum hemp-derived CBD product collection launching features: Happy Dance Whipped Body Butter (200mg CBD) - $30. Happy Dance Head-to-Toe Coconut Melt (225mg CBD) - $25. Happy Dance Stress Away Bath Bomb (60mg CBD) - $15. Happy Dance’s commitment to self-care extends not only to its products, but to the community it serves. 1% of profits from sales on the Happy Dance website will benefit A New Way of Life Re-Entry Project, a Black-owned LA-based organization that provides housing, case management, pro bono legal services, advocacy and leadership development for women rebuilding their lives after prison. Happy Dance products undergo extensive third-party testing, are vegan and cruelty-free and tested for heavy metals, microbiological contaminants, residual solvents and pesticides. Each product formula is evaluated through clinical testing according to cosmetic industry standards. Every product also features traceable lot codes allowing customers to review product Certificates of Analysis (COA).Is New 90 Day High Low • Sep 26New 90-day low: €4.30The company is down 22% from its price of €5.50 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.26 per share.お知らせ • Sep 10Cronos Group Inc. Appoints Kurt Schmidt as Chief Executive OfficerCronos Group Inc. announced that its Board of Directors has appointed Kurt Schmidt, Chief Executive Officer of the Company, effective September 9, 2020. Kurt brings to Cronos Group more than three decades of experience leading and growing renowned global consumer packaged goods companies and their brands, including at Blue Buffalo Company Ltd., Nestlé S.A., Gerber and Kraft Foods.株主還元7CIDE PharmaceuticalsDE 市場7D7.5%6.4%3.9%1Y37.0%26.5%2.6%株主還元を見る業界別リターン: 7CI過去 1 年間で26.5 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: 7CI過去 1 年間で2.6 % の収益を上げたGerman市場を上回りました。価格変動Is 7CI's price volatile compared to industry and market?7CI volatility7CI Average Weekly Movement6.1%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market12.9%10% least volatile stocks in DE Market2.7%安定した株価: 7CI 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 7CIの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a610Mike Gorensteinthecronosgroup.comカンナビノイド企業であるクロノス・グループ社は、カナダ、イスラエル、および国際的な大麻製品の栽培、生産、流通、マーケティングに従事している。同社はSpinach、Lord Jones、PEACE NATURALSのブランド名でドライフラワー、プレロール、オイル、ヴェポライザー、エディブル、大麻チンキを提供している。本拠地はカナダのステイナー。もっと見るCronos Group Inc. 基礎のまとめCronos Group の収益と売上を時価総額と比較するとどうか。7CI 基礎統計学時価総額€876.87m収益（TTM）-€1.56m売上高(TTM)€137.04m6.5xP/Sレシオ-567.8xPER（株価収益率7CI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7CI 損益計算書（TTM）収益US$159.54m売上原価US$96.34m売上総利益US$63.20mその他の費用US$65.01m収益-US$1.82m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0049グロス・マージン39.61%純利益率-1.14%有利子負債／自己資本比率0%7CI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 14:18終値2026/05/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cronos Group Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Jesse PytlakATB Cormark Historical (Cormark Securities)Vahan AjamianBeacon Securities LimitedNadine SarwatBernstein13 その他のアナリストを表示
お知らせ • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.
お知らせ • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.
お知らせ • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.
お知らせ • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.
お知らせ • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.
お知らせ • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.
お知らせ • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.
お知らせ • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.
お知らせ • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.
お知らせ • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.
お知らせ • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.
お知らせ • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.
お知らせ • Oct 28Cronos Group Inc. Brings Back Popular, Limited-Edition Spinach Green Apple-Flavored Products for the Fall SeasonCronos Group Inc. announced that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet caramel and tart-green apple flavors and is perfect for the autumn months, follows its successful launch in Fall 2024. In addition to bringing back the original SOURZ by Spinach Caramel Green Apple 5-pack of gummies, Cronos is expanding its Fall season exclusive offerings with two new products: SOURZ by Spinach Fully Blasted Caramel Green Apple 10mg THC gummy; Spinach Sweet Green Apple 1g vape (Sativa): Infused with liquid diamonds and featuring crisp green apple flavor notes. These limited-time, seasonal Spinach products are available now across Canada.
お知らせ • Oct 09Cronos Group Inc. Launches Sourz by Spinach Fully Blasted MultipacksCronos Group Inc. announced that its popular SOURZ by Spinach Fully Blasted gummies will now be available in new multipack formats. The SOURZ by Spinach fully Blasted Multipacks with liquid diamond-infused gummies are now available in five of its most popular flavors, offering consumers more choice, convenience, and value when purchasing Canada's favorite cannabis edible. SOURZ by Spinach Fully Blasted Multipacks with Liquid diamond-infused gummies will be available in 5- and 10-packs in the following flavors: 10-Pack (10 x 10mg THC gummies): SOURZ by Spinach Fully Blasted Blue Raspberry Watermelon gummies; SOURZ by Spinach Fully Blasted Pink Lemonade gummies; SOUR Z by Spinach FullyBlasted Strawberry Mango gummies: SOURZ by spinach Fully Blasted Peach Orange gummies; 5-Pack (5 x 10mg THC gummies); SOURZ by Spinach- Fully Blasted Blue Raspberry Water Watermelon gummies; SourZ by Spinach fully Blasted Pink Lemonade gibles; SOURZ by SpinACH Fully Blasted Strawberry Mango gummies; SOURZ By Spinach Fully Blasting Peach Orange gummies; 5 -Pack (5 x 10mgTH gummies); SOURZ By Spinach Fully Blasting Peach Orange Gummies; 5-Pack (5 x 10mg THC gummies; SOURZby Spinach Fully Blast Blue Raspberry Watermelon gummies and SOURZ by Spinach? Fully Blasted Pink Lemonades gummies. The SOURZ by spinach Fully Blasted Multipack with liquid diamond-infused Gummies are available now in Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan.
お知らせ • Aug 07Cronos Group Inc. Appoints Lloyd Wilson as the Principal Accounting Officer, Effective as of August 7, 2025Cronos Group Inc. Appointed Lloyd Wilson, Vice President, Controller, as the Company’s principal accounting officer, effective as of August 7, 2025. Lloyd is a seasoned financial leader and licensed Chartered Public Accountant with over 20 years of experience in financial reporting, internal audit, plant controllership, and operational finance. With a strong background in consumer-packaged goods and previous experience as a plant controller, Lloyd most recently served as a Corporate Controller, where he oversaw financial reporting, internal controls, and policy implementation.
お知らせ • May 09Cronos Group Inc. (TSX:CRON) announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.Cronos Group Inc. (TSX:CRON) announces a share repurchase program. Under the program, the company will repurchase up to 19,270,951 shares representing 5% of it's issued share for $50 million. The repurchases will be made from available funds. The repurchase program is valid till May 13, 2026.
お知らせ • Apr 23Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare CannabinoidsCronos Group Inc.'s best-selling cannabis brand, Spinach®?, introduced three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach®? Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio. Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio; Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.; Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach®? vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience. In addition to the Spinach®? vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach™?, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors: Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy.
お知らせ • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2025Cronos Group Inc., Annual General Meeting, Jun 20, 2025.
お知らせ • Mar 20Cronos Group Inc. Announces Chief Financial Officer ChangesCronos Group Inc. announced the appointment of Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success. Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.
Reported Earnings • Nov 14Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.004 loss in 3Q 2023)Third quarter 2024 results: EPS: US$0.02 (up from US$0.004 loss in 3Q 2023). Revenue: US$34.3m (up 38% from 3Q 2023). Net income: US$8.35m (up US$9.81m from 3Q 2023). Profit margin: 24% (up from net loss in 3Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Aug 28Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across CanadaCronos Group Inc. is expanding its portfolio for its Lord Jones brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. The Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes: Lord Jones Ice Water Hash Fusions Pre-Rolls: Sour Blueberry x Sour Blueberry. 1g ice water hash flower pre-roll with blueberry and gas flavor notes. Indica | THC: 35-41% | 1x1g. Snow Lotus x Animal Mints. 1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes. Hybrid | THC: 35-41% | 1x1g Lord Jones Live Resin Vapes (All-in-One and 510-Cartridge): Gorilla Z Live Resin Vape A flavor-forward vape designed to boast an promoted berry, cherry, and grape flavor experience. Hybrid | 70+% THC . Available in two hardware options that are optimized for live resin usage: A sleek 0.5g all-in-one device. A high-quality 1g 510-thread cartridge.
Breakeven Date Change • Aug 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$24.7m in 2026.
Reported Earnings • Aug 09Second quarter 2024 earnings released: US$0.02 loss per share (vs US$0.015 loss in 2Q 2023)Second quarter 2024 results: US$0.02 loss per share (further deteriorated from US$0.015 loss in 2Q 2023). Revenue: US$27.8m (up 46% from 2Q 2023). Net loss: US$8.76m (loss widened 59% from 2Q 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 5 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.
Breakeven Date Change • Jul 13No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.47m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.
Breakeven Date Change • Jul 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.69m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.
お知らせ • Jun 28Cronos Group Inc. Brand Spinach®? Celebrates Summer with New LaunchesCronos Group Inc.'s Spinach®? brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach®? edibles and a premier milled flower product. The new SOURZ by Spinach™? Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ®? flavors, now with 10 mg of THC per piece. The SOURZ by SpinACH®? Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach®? "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. SOURZ by SpinachTM Fully Blasted includes one 10 mg THC gummy per package in the following flavors: Pink Lemonade; Sweet and refreshing flavors of raspberry and lemonade; Blue Raspberry Watermelon; Electric blue raspberry and refreshing watermelon; Cherry Lime; Delightful cherry and tangy lime. SOURZ by SpinACH™? Tropical Party Pack: 1 mg THC per gummy, 10 mg THC per pack; Featuring three new dual-flavors: Peach Passionfruit, Pineapple Coconut, and Strawberry Guava. Additionally, the Spinach®? brand will introduce Spinach®?, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™? caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience. Spinach Grindz®? are now available in the following strains: Citrus Crush; Milled flower with citrus, sour, and earthy notes; Cookie Dough; Milled flower with sweet, nutty, and creamy notes.
お知らせ • Jun 22Cronos Group Inc. Elects Murray Garnick as DirectorCronos Group Inc. at its Annual Meeting of Shareholders held on June 20, 2024, approved to elect Murray Garnick as director.
Breakeven Date Change • May 12Forecast breakeven date moved forward to 2025The 8 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 87% to 2024. The company is expected to make a profit of US$5.67m in 2025. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • May 10First quarter 2024 earnings released: US$0.01 loss per share (vs US$0.05 loss in 1Q 2023)First quarter 2024 results: US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023). Revenue: US$25.3m (up 26% from 1Q 2023). Net loss: US$2.24m (loss narrowed 88% from 1Q 2023). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 07No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.71m in 2026. New consensus forecast suggests the company will make a loss of US$1.60m in 2026.
New Risk • Mar 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2024Cronos Group Inc., Annual General Meeting, Jun 20, 2024.
お知らせ • Mar 26Cronos Group Inc. Launches Lord Jones Chocolate FusionsCronos Group Inc. announced the launch of Lord Jones Chocolate Fusions, its exciting first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi- texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Lord Jones Chocolate Fusions feature winning attributes to attract cannabis consumers, including three delicious flavor combinations, an artisanal design that highlights a creative combination of textures, and a flavor-masking system to ensure outstanding taste. Through an extensive research and sensory testing process, team of experts seized the opportunity to deliver an exceptional edible that elevates the overall category. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Chocolate Fusions will be available in the following flavors and formats: Lord Jones Cookies & Cream Chocolate Fusions, 10mg THC total per package, Three layers of white chocolate, cookie crunch bits, and a chewy fudge center, Lord Jones Salted Caramel Crunch 1:1 CBD | THC Chocolate Fusions, 10mg CBD per package, 10mg THC and 10mg CBD per package, Three layers of milk chocolate, a sweet and salty crunch, and a smooth caramel center, Lord Jones Dazzleberry Pop Chocolate Fusions, 10mgTH total per package, Three layers the gold-dusted dark chocolate, a crackling pop, and a sweet berry center. Cronos continues to be an award-winning leader in cannabis edibles. The same team behind the hugely popular SOURZ by Spinach® and Spinach FEELZTM portfolio of gummies leveraged their expertise in the edibles space to create this innovation for the chocolate category for the Lord Jones® brand.
Breakeven Date Change • Mar 03Forecast breakeven date moved forward to 2025The 6 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 79% to 2024. The company is expected to make a profit of US$11.0m in 2025. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$236.3k in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
お知らせ • Dec 15Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware OptionsCronos Group Inc. announced the launch of its highly anticipated Lord Jones Live Resin Vapes in two different hardware options. Crafted with the discerning cannabis consumer in mind, these products embody a commitment to excellence, offering an unmatched combination of curated strains, pure live resin, and elegant high-quality hardware. The live resin format offers consumers a multi-dimensional, true-to-plant experience. This format is well suited for discerning consumers looking to level-up their cannabis experience. These vapes feature consistent high potency, with THC levels exceeding 70%, and advanced hardware designed to optimize live resin consumption, preserving terpenes and preventing clogging. The lineup also features versatile sizing options, including a 0.5g trial size in the convenience of an all-in-one device and a 1g stock-up size as a 510-thread cartridge, catering to both enthusiasts and those new to the category. Lord Jones Live Resin Vape are available in the following formats: Lord Jones Purple Lemon Haze Live Resin Vapes; Designed to deliver a supremely elevated experience, with notes of zesty citrus, pleasant earthiness, and sharp and spicy pepper flavors; Sativa | THC: 72-78% Available in two hardware options that have been optimized for live resin usage: A unique sleek 0.5g all-in-one device; A high-quality 1g 510-thread cartridge; Lord Jones Deadhead OG Live Resin Vapes; designed to deliver a truly complex flavor experience with savory, spicy, and woody flavors; Indica | THC: 71-77% Available in two hardware options That have been optimized for live resin use: A unique sleek 0. 5g all-in-one devices will be available in Alberta, Manitoba, Ontario, Saskatchewan and Yukon in 2024. Lord Jones batteries will be available in Manitoba, Ontario, Saskatchewan andYukon by early 2024. Lord Jones batteries will been available in Manitoba, Ontario, Alberta, Ontario, Saskatchewan and YukON by early 2024.
お知らせ • Nov 29Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million on November 26, 2023. The aggregate purchase price will be paid as CAD 0.1 million will be paid in trust within two business days of the date of the Sale Agreement (b) CAD 1 million will be paid in trust within five business days of the waiver or satisfactions of the Buyer’s Condition, the Seller’s Condition and the Lease Condition (each, as defined below) and (c) the balance of the aggregate purchase price will be paid at the closing. Closing is expected to occur on the first business day that falls 30 calendar days following the later of (i) the satisfaction or waiver of the Buyer’s Condition or (ii) the satisfaction or waiver of the Seller’s Condition.
Breakeven Date Change • Nov 11Forecast to breakeven in 2025The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of US$7.29m in 2025. Average annual earnings growth of 92% is required to achieve expected profit on schedule.
Reported Earnings • Nov 09Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022)Third quarter 2023 results: US$0.005 loss per share (improved from US$0.098 loss in 3Q 2022). Revenue: US$24.8m (up 19% from 3Q 2022). Net loss: US$1.46m (loss narrowed 96% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Nov 04Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis MarketCronos Group Inc. announced that it has launched its award-winning cannabis brand Lord Jones® in the Canadian adult-use cannabis market. The Lord Jones® brand will build on its legacy of delivering premium quality cannabis products by returning to its roots with bold THC-focused product innovations. The first Lord Jones® product to launch in Canada are Lord Jones® Hash Fusions pre-rolls. The popularity of hash products and premium pre-rolls is increasing amongst adult consumers. Hash is currently the most popular solventless infusion and is the second most popular infusion overall in the pre-roll category. The Lord Jones® Hash Fusions pre-rolls go beyond delivering an elevated, true-to-plant consumption experience. These pre-rolls are crafted with an optimized ratio of premium high-potency flower and complementary solventless ice water hash, which preserves the buds’ natural terpenes, fitted with a reusable ceramic tip to help cool the smoke. This new product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. Lord Jones® Hash Fusions pre-rolls are available in the following formats: Lord Jones® Hash Fusions – White Tahoe OG Flower x White Tahoe OG Ice Water Hash; Indica | THC: 35 – 40% | 1x1g; Lord Jones® Hash Fusions – Cosmic Kush Flower x Platinum GMO Ice Water Hash; Hybrid | THC: 35 – 40%+| 1x1g.
お知らせ • Oct 31Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full TiltCronos Group Inc. announced the launch of two new THCV-infused products; Spinach FEELZ Full Tilt THCV vape and gummy. Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ brand, which will add an additional offering under its robust and growing pre-roll portfolio. The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience. The Spinach FEELZ full Tilt product range includes: Spinach FEELZ FullTilt Blue Razz Durban 7:1 THC|THCV vape; 700mg of THC and 100mg of THCV per 1g cartridge; Spinach FEELZ fullTilt Blue Raspberry Lemonade 1:2 THC|THCV gummies; 5 pieces/pack with 10mg of THC and 20mg THCV per pack. The THCV vape is now available in Alberta, British Columbia, and Ontario and the THCV edibles are available now in Ontario and British Columbia and will be available in Alberta by November 30. THC infused pre-rolls are planned for launch in 2024. Through Spinach FEELZ, Cronos is committed to bringing a full line of products featuring rare cannabinoids to consumers in a wide range of product formats. Each product is designed to deliver unique and enhanced experiences made possible through proprietary blends of rare cannabinoids alongside more well-known cannabinoids, like THC and CBD. Each product is formulated to help adult consumers, "Feelz. The Way You want." With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®?, PEACE NATURALS®? and Lord Jones®?.
お知らせ • Aug 10Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023Cronos Group Inc. revised earnings guidance for the full year 2023. For the year, the company has decided to discontinue providing net revenue guidance and to withdraw previously announced net revenue target of $100 million to $110 million for full-year 2023. The discontinuance of providing net revenue guidance reflects turbulent market conditions beyond previous expectations in the markets in which Company operate, specifically, increasing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada. In addition, foreign exchange rates have had unfavorable impact on Company's net revenue.
Reported Earnings • Aug 09Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.054 loss in 2Q 2022)Second quarter 2023 results: US$0.013 loss per share (improved from US$0.054 loss in 2Q 2022). Revenue: US$19.0m (down 18% from 2Q 2022). Net loss: US$5.53m (loss narrowed 73% from 2Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 07Cronos Reportedly Explores Possible Sale After Attracting Takeover InterestCronos Group Inc. (TSX:CRON), the Canadian cannabis producer backed by cigarette maker Altria Group Inc. (MO.N), is exploring options that include a potential sale after attracting acquisition interest, people familiar with the matter said. Toronto-based Cronos is working with a financial adviser to handle the expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc. (CURA.CD), the sources said. The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain. Cronos and Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment.
お知らせ • May 20Cronos Group Inc. Announces Executive ChangesOn May 18, 2023, Cronos Group Inc. appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023. On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023. Prior to joining the Company, Mr. McGinness, age 45, was the Acting Chief Financial Officer and Vice President, Corporate Controller for MarketWise Inc. since April 2019. While at MarketWise, Mr. McGinness was responsible for the Accounting, Tax, External and Internal Financial Reporting, Investor Relations, and Financial Planning and Analysis functions and was instrumental in restructuring and developing a world-class finance organization while shepherding MarketWise through an Up-C SPAC transaction and several other strategic transactions. Prior to MarketWise, Mr. McGinness served as Corporate Controller at GSE Systems from August 2016 until November 2018 and previously held various management roles at Exelon, Washington Gas, T. Rowe Price and McCormick. Mr. McGinness is a CPA and earned a Bachelor of Science in Accounting from the State University of New York at Albany.
お知らせ • May 10Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023Cronos Group Inc. Provided revenue guidance for the full year 2023. For the year, the company expected to be between $100 million to $110 million.
Reported Earnings • May 09First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.087 loss in 1Q 2022)First quarter 2023 results: US$0.10 loss per share. Revenue: US$20.1m (down 20% from 1Q 2022). Net loss: US$19.2m (loss narrowed 41% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Mar 01Full year 2022 earnings released: US$0.45 loss per share (vs US$1.07 loss in FY 2021)Full year 2022 results: US$0.45 loss per share (improved from US$1.07 loss in FY 2021). Revenue: US$91.9m (up 24% from FY 2021). Net loss: US$168.7m (loss narrowed 57% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance.
Board Change • Jan 25Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kendrick Ashton was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director Kendrick Ashton was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.054 loss per share (vs US$0.48 loss in 2Q 2021)Second quarter 2022 results: US$0.054 loss per share (up from US$0.48 loss in 2Q 2021). Revenue: US$23.1m (up 48% from 2Q 2021). Net loss: US$20.2m (loss narrowed 89% from 2Q 2021). Over the next year, revenue is forecast to grow 34%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 09Second quarter 2021 earnings released: EPS US$0.15 (vs US$0.31 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$15.6m (up 58% from 2Q 2020). Net income: US$57.6m (up US$164.5m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Executive Departure • Jul 13Executive Officer Puneet Mathur has left the companyOn the 30th of June, Puneet Mathur's tenure as Executive Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Puneet's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.46 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.22 profit in 1Q 2020)The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: US$12.6m (up 50% from 1Q 2020). Net loss: US$161.3m (down 312% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.
Recent Insider Transactions • Mar 17Executive Chairman recently sold €5.2m worth of stockOn the 15th of March, Michael Gorenstein sold around 604k shares on-market at roughly €8.67 per share. This was the largest sale by an insider in the last 3 months. Michael has been a seller over the last 12 months, reducing personal holdings by €13m.
Recent Insider Transactions • Mar 05Insider recently sold €51k worth of stockOn the 1st of March, Jeffrey Jacobson sold around 5k shares on-market at roughly €11.28 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €14m more than they bought in the last 12 months.
Reported Earnings • Feb 28Full year 2020 earnings released: US$0.20 loss per share (vs US$3.76 profit in FY 2019)The company reported a mediocre full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$46.7m (up 97% from FY 2019). Net loss: US$72.5m (down 106% from profit in FY 2019). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Analyst Estimate Surprise Post Earnings • Feb 28Revenue beats expectationsRevenue exceeded analyst estimates by 7.9%. Over the next year, revenue is forecast to grow 86%, compared to a 2.1% growth forecast for the Pharmaceuticals industry in Germany.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to US$10.20, the stock is trading at a trailing P/E ratio of 45.6x, down from the previous P/E ratio of 57x. This compares to an average P/E of 26x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 76%.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to US$10.44, the stock is trading at a trailing P/E ratio of 42.5x, up from the previous P/E ratio of 34.7x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 79%.
Is New 90 Day High Low • Feb 03New 90-day high: €9.50The company is up 75% from its price of €5.43 on 05 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €20.51 per share.
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$9.25, the stock is trading at a trailing P/E ratio of 38.7x, up from the previous P/E ratio of 33.6x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 24%.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$8.88, the stock is trading at a trailing P/E ratio of 37x, up from the previous P/E ratio of 31.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 35%.
Is New 90 Day High Low • Jan 07New 90-day high: €7.52The company is up 54% from its price of €4.87 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.65 per share.
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improved over the past weekAfter last week's 22% share price gain to US$7.06, the stock is trading at a trailing P/E ratio of 26.1x, up from the previous P/E ratio of 21.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total return to shareholders over the past three years is a loss of 22%.
Is New 90 Day High Low • Dec 04New 90-day high: €7.22The company is up 62% from its price of €4.46 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.17 per share.
Valuation Update With 7 Day Price Move • Nov 27Market bids up stock over the past weekAfter last week's 17% share price gain to US$7.00, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 137%.
Recent Insider Transactions • Nov 12Executive Chairman recently sold €7.8m worth of stockOn the 6th of November, Michael Gorenstein sold around 1m shares on-market at roughly €6.08 per share. This was the largest sale by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 22% share price gain to US$5.76, the stock is trading at a trailing P/E ratio of 3.7x, up from the previous P/E ratio of 3x. This compares to an average P/E of 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 102%.
Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 18% share price gain to US$5.43, the stock is trading at a trailing P/E ratio of 2.9x, up from the previous P/E ratio of 2.4x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Europe. Total returns to shareholders over the past three years are 148%.
Is New 90 Day High Low • Nov 05New 90-day high: €5.09The company is up 1.0% from its price of €5.04 on 06 August 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.25 per share.
お知らせ • Oct 15Cronos Group Inc. Announces the Launch of Happy Dance, A New, Clean, Simple CBD Skincare Brand, Co-Founded with Actress and New York Times Best-Selling Author Kristen BellCronos Group Inc. announced the launch of Happy Dance, a new, clean, simple CBD skincare brand, co-founded with actress and New York Times best-selling author Kristen Bell. Happy Dance launches with a trio of high-quality, cruelty-free and vegan bath and body care products. The new Happy Dance collection features a body butter, a coconut melt and a bath bomb, all formulated with Kristen Bell’s favorite clean ingredients and high-quality CBD from full-spectrum hemp extract. These multi-purpose products are infused with delightful blends of plant-based oils and butters in enjoyable textures that are effortlessly easy-to-use. The ultimate head-to-toe body treats, Happy Dance products are perfectly suited for the CBD enthusiast or for someone experiencing CBD for the first time. The Happy Dance brand is the epitome of good, clean, fun. The full-spectrum hemp-derived CBD product collection launching features: Happy Dance Whipped Body Butter (200mg CBD) - $30. Happy Dance Head-to-Toe Coconut Melt (225mg CBD) - $25. Happy Dance Stress Away Bath Bomb (60mg CBD) - $15. Happy Dance’s commitment to self-care extends not only to its products, but to the community it serves. 1% of profits from sales on the Happy Dance website will benefit A New Way of Life Re-Entry Project, a Black-owned LA-based organization that provides housing, case management, pro bono legal services, advocacy and leadership development for women rebuilding their lives after prison. Happy Dance products undergo extensive third-party testing, are vegan and cruelty-free and tested for heavy metals, microbiological contaminants, residual solvents and pesticides. Each product formula is evaluated through clinical testing according to cosmetic industry standards. Every product also features traceable lot codes allowing customers to review product Certificates of Analysis (COA).
Is New 90 Day High Low • Sep 26New 90-day low: €4.30The company is down 22% from its price of €5.50 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €1.26 per share.
お知らせ • Sep 10Cronos Group Inc. Appoints Kurt Schmidt as Chief Executive OfficerCronos Group Inc. announced that its Board of Directors has appointed Kurt Schmidt, Chief Executive Officer of the Company, effective September 9, 2020. Kurt brings to Cronos Group more than three decades of experience leading and growing renowned global consumer packaged goods companies and their brands, including at Blue Buffalo Company Ltd., Nestlé S.A., Gerber and Kraft Foods.
